drugset / Trial / NCT04347174
A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients
Completed
40 enrolled
Cadila Pharnmaceuticals
Council of Scientific and Industrial Research, India · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The trial is randomized, blinded, two arms, active comparator controlled, clinical trial to evaluate the safety and efficacy of Mycobacterium w in combination with standard care as per hospital practice versus standard care alone in critically ill adult patients suffering from COVID-19 infection.
Timeline
- Start
- 2020-04-30
- Primary completion
- 2020-08-10
- Completion
- 2020-08-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mycobacterium w | Vaccine | 0.3 ml | Other |